A Randomized Double-Blind Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma
This randomized phase III trial is studying gemcitabine hydrochloride, cisplatin, and
bevacizumab to see how well they work compared with gemcitabine hydrochloride, cisplatin,
and placebo in treating patients with advanced urinary tract cancer. Drugs used in
chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. It is not yet known whether
gemcitabine hydrochloride and cisplatin are more effective when given together with or
without bevacizumab in treating patients with urinary tract cancer.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.